A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma

Trial Profile

A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs CYT 001 (Primary) ; Eftilagimod alpha (Primary) ; Poly ICLC (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Apr 2018 New trial record
    • 16 Mar 2018 According to a CYTLIMIC media release, based on the data from YNP01 study, the company has started this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top